Rene M. Rodriguez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Retraction notice to "Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways" [Biomedicine & Pharmacotherapy 161 (2023) 114512].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 17, 2026

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.

Journal: Drug delivery
Published: May 12, 2026

Hippo signalling pathway mediates oncogenic properties of NAB2::STAT6 in solitary fibrous tumour.

Hippo signalling pathway mediates oncogenic properties of NAB2::STAT6 in solitary fibrous tumour.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: December 01, 2025

Hippo signalling pathway mediates oncogenic properties of NAB2::STAT6 in solitary fibrous tumour.

Hippo signalling pathway mediates oncogenic properties of NAB2::STAT6 in solitary fibrous tumour.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: December 01, 2025

Chondrosarcoma: Multi-Targeting Therapeutic Effects of Doxorubicin, BEZ235, and the Small Molecule Aspartyl-Asparaginyl-β-hydroxylase Inhibitor SMI1182.

Chondrosarcoma: Multi-Targeting Therapeutic Effects of Doxorubicin, BEZ235, and the Small Molecule Aspartyl-Asparaginyl-β-hydroxylase Inhibitor SMI1182.

Journal: Cancers
Published: April 13, 2025

Chondrosarcoma: Adjuvant Therapeutic Effects of the ASPH Small Molecule Inhibitor, SMI-1182, With Doxorubicin.

Chondrosarcoma: Adjuvant Therapeutic Effects of the ASPH Small Molecule Inhibitor, SMI-1182, With Doxorubicin.

Journal: Japanese journal of cancer and oncology research
Published: January 01, 2025

GPX1 expression promotes stemness and aggressiveness in myxoid liposarcomas.

GPX1 expression promotes stemness and aggressiveness in myxoid liposarcomas.

Journal: International journal of biological sciences
Published: October 14, 2024

Proteomics analysis of human mesenchymal stromal/stem cell sarcomagenesis model identifies ALDH1A3 and CD99 as potential targets in the transformation process.

Proteomics analysis of human mesenchymal stromal/stem cell sarcomagenesis model identifies ALDH1A3 and CD99 as potential targets in the transformation process.

Journal: BMC biology
Published: June 22, 2024

Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells.

Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells.

Journal: Free radical biology & medicine
Published: August 16, 2023

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.

Journal: EBioMedicine
Published: July 07, 2023

Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma.

Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma.

Journal: Redox biology
Published: February 28, 2023

Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways.

Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 27, 2023
Showing 1-12 of 51

Last Updated: 09/26/2026